Abstract
At the blood-brain barrier, ATP-binding cassette (ABC) transporters, such as, P-glycoprotein (MDR1, ABCB1) and breast cancer related protein (BCRP, ABCG2) limit CNS uptake of foreign chemicals. Thus, they are neuroprotective, but they also distinguish poorly between neurotoxicants and therapeutic drugs. So they are major obstacles to CNS pharmacotherapy. The present review is focused on new findings in animal models in vitro and in vivo showing that basal transport activity of P-glycoprotein and Bcrp can be rapidly and transiently reduced through targeting of specific signaling pathways within the brain capillary endothelium. Three pathways have been identified: estrogen signaling to Bcrp, vascular endothelial growth factor signaling to P-glycoprotein and TNFα/PKC/ sphingolipid signaling to P-glycoprotein. Translation of these results to the clinic could provide improved pharmacotherapy for a number of CNS diseases, including, brain cancer, neuroAIDS and epilepsy.
Keywords: Neuroprotection, Drug delivery, ABC transporters, Blood-brain barrier, P-gp, efflux pumps.
Current Pharmaceutical Design
Title:Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Volume: 20 Issue: 10
Author(s): David S. Miller and Ronald E. Cannon
Affiliation:
Keywords: Neuroprotection, Drug delivery, ABC transporters, Blood-brain barrier, P-gp, efflux pumps.
Abstract: At the blood-brain barrier, ATP-binding cassette (ABC) transporters, such as, P-glycoprotein (MDR1, ABCB1) and breast cancer related protein (BCRP, ABCG2) limit CNS uptake of foreign chemicals. Thus, they are neuroprotective, but they also distinguish poorly between neurotoxicants and therapeutic drugs. So they are major obstacles to CNS pharmacotherapy. The present review is focused on new findings in animal models in vitro and in vivo showing that basal transport activity of P-glycoprotein and Bcrp can be rapidly and transiently reduced through targeting of specific signaling pathways within the brain capillary endothelium. Three pathways have been identified: estrogen signaling to Bcrp, vascular endothelial growth factor signaling to P-glycoprotein and TNFα/PKC/ sphingolipid signaling to P-glycoprotein. Translation of these results to the clinic could provide improved pharmacotherapy for a number of CNS diseases, including, brain cancer, neuroAIDS and epilepsy.
Export Options
About this article
Cite this article as:
Miller S. David and Cannon E. Ronald, Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990457
DOI https://dx.doi.org/10.2174/13816128113199990457 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Pediatric Chronic Daily Headache
Current Pediatric Reviews Diagnostic Properties and Significance of Tongue in Persian Medicine and Chinese Medicine
Current Traditional Medicine Genetic Studies on the Role of T-Type Ca2+ Channels in Sleep and Absence Epilepsy
CNS & Neurological Disorders - Drug Targets Adult Neurogenesis and Drug Therapy
Central Nervous System Agents in Medicinal Chemistry Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets A One Pot Green Synthesis of 3,4 Dihydropyrimidin-2-(1H)-ones/Thiones Catalyzed By MgO-ZrO<sub>2</sub> Under Solvent-Free Conditions
Letters in Organic Chemistry On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Approaches to Mitochondrial Gene Therapy
Current Gene Therapy An EJC Factor RBM8a Regulates Anxiety Behaviors
Current Molecular Medicine Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Central Nervous System Agents in Medicinal Chemistry Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design